Latest Preotact Stories

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The...

THOUSAND OAKS, Calif., Sept. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia(®) (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the first FDA-approved RANK Ligand inhibitor, is a subcutaneous injection administered by a health care professional every six months. "While osteoporosis and osteoporosis-related fractures are more...

Foundation Urges Patients Not to Stop Treatment without Talking to their Healthcare Provider; Experts Available for Comment WASHINGTON, May 10, 2012 /PRNewswire-USNewswire/ -- In response to the Perspectives pieces published online today by the New England Journal of Medicine, the National Osteoporosis Foundation (NOF), the nation's leading community health organization dedicated to preventing osteoporosis and broken bones, commends the U.S. Food and Drug Administration (FDA) for its...

The U.S. Preventive Services Task Force and other organizations have recommended that women ages 65 and older be routinely screened for osteoporosis using bone mineral density (BMD) screening. However, how often women should be screened is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance. Now a new study led by Margaret L. Gourlay, MD, MPH of the University of North Carolina at Chapel Hill School of Medicine finds that women aged...

BOONTON, N.J., Nov. 9, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced positive top-line results of its Phase 2 clinical study evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in 93 postmenopausal women. The study achieved its primary endpoint with statistical significance. The Phase 2 study was conducted by Unigene as...

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was associated with continued increase in bone mineral density (BMD) and consistent reduction in markers of bone turnover. These results will be presented on Nov. 8, 2011, at the 2011 American...

FREMONT, Calif. and TOKYO, Oct. 10, 2011 /PRNewswire/ -- Zosano Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) announced today that they have entered into a long-term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of Teribone(TM) (teriparatide acetate), AKP's formulation of human parathyroid hormone (human PTH 1-34), for the treatment of osteoporosis patients with a high risk of fracture. Under...

THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. In patients...

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth...

By: Rhonda Craig, Ivanhoe Health Correspondent(Ivanhoe Newswire) -- The same medicines used to treat angina and chronic heart failure, may also help treat osteoporosis. In this new study, researchers found that postmenopausal women that used nitroglycerin ointment for two years experienced a modest increase in bone mineral density and decrease in bone loss.According to study authors, the number of osteoporotic fractures is increasing, and an inexpensive and widely available treatment like...